Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
BMC Cancer|April 10, 2024
First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumorsYe Guo, Zishu Wang, Huan Zhou, et al.
Journal of the American Chemical Society|April 12, 2023
Photoresponse of Solution-Synthesized Graphene Nanoribbon Heterojunctions on Diamond Indicating Phototunable Photodiode PolarityXiaoxi Zhang, Yunbin Hu, Carlos R Lien-Medrano, et al.
Frontiers in Pharmacology|March 9, 2026
Efficacy and safety of camrelizumab-based regimens in advanced squamous cell carcinoma patients: a prospective multicenter studyWeijia Jiang, Wanren Peng, Dong Qian, et al.
Signal Transduction and Targeted Therapy|May 6, 2025
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trialYuankai Shi, Yi Ba, Junye Wang, et al.
Cancer Immunology, Immunotherapy : CII|March 8, 2025
Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studiesZhihao Lu, Guoping Sun, Jiancheng Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2023
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic CancerShukui Qin, Jin Li, Yuxian Bai, et al.
Cancer Management and Research|August 22, 2020
Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from ChinaWanren Peng, Fenglin Zhang, Zishu Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2021
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III TrialShukui Qin, Feng Bi, Shanzhi Gu, et al.
The Lancet. Gastroenterology & Hepatology|May 10, 2021
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialShukui Qin, Qiu Li, Shanzhi Gu, et al.
European Journal of Medical Research|October 30, 2025
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 studyFeng Bi, Shukui Qin, Shanzhi Gu, et al.
Pageof 8